Sanofi Consumer Healthcare India Q4 FY25 Result: Share Price Jump 15.10%, ₹75 Dividend Declared

Sanofi Consumer Healthcare India Limited (BSE: 544250 | NSE: SANOFICONR) shares surged 15.10% to ₹4,614.50 as of 2:04 pm IST on February 26, 2026, gaining ₹605.30 from the previous close of ₹4,009.20. The rally followed the company’s regulatory filing confirming audited financial results for the quarter and financial year ended December 31, 2025, along with a final dividend announcement.

Why Sanofi Consumer Healthcare India Share Price Moved

The stock reacted after the company reported a 50% year-on-year (YoY) rise in Q4 FY25 Net Profit (Profit After Tax) to ₹665 million, as disclosed in its press release submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Quarterly revenue rose 47% YoY to ₹2,510 million. Domestic sales increased 23% during the quarter, while export sales growth was supported by a low base, according to the filing.

For the full year FY25, revenue stood at ₹8,784 million, up 21% YoY, while Net Profit (PAT) rose 33% YoY to ₹2,401 million. The board also declared a dividend of ₹75 per share for the year ended 31 December 2025. The earnings growth alongside the dividend announcement appears to have driven the move.

Sanofi Consumer Healthcare India Stock Performance Snapshot

As of 2:04 pm IST, the stock traded at ₹4,614.50 on the NSE, up 15.10% over the previous close.

The share opened at ₹4,240.00 and touched an high of ₹4,811.00 and a low of ₹4,231.00 so far during the session. The previous close stood at ₹4,009.20, as per exchange data.

What this Means for Investors

The 50% YoY increase in Q4 FY25 Net Profit (PAT) indicates improved quarterly profitability compared with the corresponding period last year. The company attributed performance to revenue growth, domestic sales expansion and improved product mix, as referenced in management commentary within the press release.

The declaration of a ₹75 per share dividend reflects cash distribution following the reported rise in annual Net Profit. Investors may monitor whether revenue momentum and margin trajectory sustain in subsequent quarters, based on future regulatory disclosures.

About Sanofi Consumer Healthcare India

Sanofi Consumer Healthcare India Limited is an India-focused consumer healthcare company that emerged as a distinct legal entity following its demerger from Sanofi India Limited on June 1, 2024. The company operates across allergy, digestive wellness, pain care and multivitamin categories.

Its portfolio includes brands such as Allegra, DePURA, Avil and Combiflam. The company is listed on the BSE under scrip code 544250 and on the NSE under the symbol SANOFICONR.

Conclusion

Sanofi Consumer Healthcare India shares advanced 15.10% on February 26, 2026 after the company reported a 50% YoY rise in Q4 FY25 Net Profit (PAT) to ₹665 million, alongside a 47% YoY increase in quarterly revenue and a ₹75 per share dividend declaration for FY25. The market reaction followed the audited results disclosure submitted to the exchanges.

Source:

• https://nsearchives.nseindia.com/corporate/SANOFICONSUMER_25022026203000_Press_Release_s.pdf
• https://www.nseindia.com/get-quote/equity/SANOFICONR/Sanofi-Consumer-Healthcare-India-Limited